Acromegaly
Welcome,         Profile    Billing    Logout  
 20 Companies   9 Products   9 Products   6 Mechanisms of Action   50 Trials   3631 News 


12345678910111213...5960»
  • ||||||||||  Somavert (pegvisomant) / Pfizer
    Trial completion date, Trial primary completion date:  PegvisOMant and the Immune SystEm (PROMISE) (clinicaltrials.gov) -  Jan 16, 2025   
    P=N/A,  N=62, Completed, 
    Extended follow-up is needed to evaluate post-SRS toxicity and hypopituitarism. Trial completion date: Jun 2023 --> Dec 2024 | Trial primary completion date: Jun 2023 --> Dec 2024
  • ||||||||||  Signifor (pasireotide) / Recordati
    Journal:  Structure and Function of Somatostatin and its Receptors in Endocrinology. (Pubmed Central) -  Jan 10, 2025   
    Somatostatin analogs, such as octreotide, lanreotide, and pasireotide, which function as somatostatin receptor ligands (SRLs), are the main drugs used for the treatment of acromegaly...The results revealed the residues that contribute to the ligand binding pocket and demonstrated that Trp8-Lys9 (the W-K motif) in somatostatin analogs is the key motif in stabilizing the bottom part of the binding pocket. In this review, we discuss the recent findings related to the structural analysis of SSTRs and SRLs, the relationships between the structural data and clinical findings, and the future development of novel structure-based therapies.
  • ||||||||||  Signifor (pasireotide) / Recordati
    Review, Journal:  Pasireotide-induced hyperglycemia in Cushing's disease and Acromegaly: A clinical perspective and algorithms proposal. (Pubmed Central) -  Dec 30, 2024   
    Based on the pathomechanism of hyperglycemia, we suggest using metformin as the first-line therapy, followed by glucagon-like peptide-1 and/or sodium-glucose co-transporter-2 inhibitor, and finally insulin in patients with pasireotide-induced hyperglycemia. We propose algorithms for the management of glucose metabolic disorders caused by pasireotide treatment in patients with CD and acromegaly, including those with chronic kidney disease and at high cardiovascular risk.
  • ||||||||||  Journal:  Pharmacological management of pituitary adenomas - what is new on the horizon? (Pubmed Central) -  Dec 24, 2024   
    In conclusion, NKX2.2 is a transcription factor that can be used as an additional tool in pituitary pathology, and PIT1 and SF1-multilineage PitNETs are specific tumors that usually present with acromegaly, show signs of a nonaggressive clinical course, have a pseudopapillary histomorphology, and express NKX2.2. No abstract available
  • ||||||||||  Somavert (pegvisomant) / Pfizer
    Journal:  Personalized medicine in acromegaly: The ACROFAST study. (Pubmed Central) -  Dec 17, 2024   
    In the pediatric population, surgery can be performed safely and efficiently via en EEN approach. Personalized medicine is feasible using a relatively simple protocol, and it allows a higher number of patients to achieve control in a shorter period of time.
  • ||||||||||  Journal:  Bioinformatic materials science reconsidered. (Pubmed Central) -  Dec 16, 2024   
    Notably, bioinformatic materials have been applied in treating acromegaly, a rare and life-threatening disease of unknown etiology, and have improved the neurofilament light chain (NFL) index and typical symptoms of Amyotrophic Lateral Sclerosis (ALS). In summary, bioinformatic materials science holds potential for enhancing human health and contributing to advances in medicine.
  • ||||||||||  Journal:  Changes in retinal microvasculature and serum Gremlin-1 levels in acromegaly: a case-control study. (Pubmed Central) -  Dec 13, 2024   
    Patients with acromegaly have decreased vascular density and lower levels of Gremlin-1 independent of glucose tolerance status. Acromegaly may cause a reduction in gremlin-1 as a compensatory mechanism due to high IGF-1 levels known as an angiogenic factor, which in turn leads to the decrease in vascular density, or gremlin-1 may already have shown a decline in response to chronic inflammation and endothelial dysfunction in acromegaly resulting in a reduction in vascular density.
  • ||||||||||  Journal:  Elevated Vitamin D leading to an Incidental Diagnosis of Multiple Myeloma. (Pubmed Central) -  Dec 12, 2024   
    Laboratory assay interferences have the potential to disrupt the accurate diagnostic workup of patients. Collaborative discussions between laboratory and clinical teams regarding such cases aid in directing the diagnostic pathway appropriately, facilitating prompt and proper diagnosis and management.
  • ||||||||||  Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
    Journal:  Pachydermoperiostosis Due to a Novel HPGD Splicing Site Mutation Masquerading as Acromegaly. (Pubmed Central) -  Dec 11, 2024   
    Reverse transcription polymerase chain reaction confirmed that this variant led to defective splicing with skipping of exon 6, a frameshift, and truncation at codon 13 of exon 7 downstream. His symptoms did not respond well to nonsteroidal anti-inflammatory drugs but showed excellent response to a trial of lanreotide autogel that has been used for about 1 year.
  • ||||||||||  Somavert (pegvisomant) / Pfizer, Signifor (pasireotide) / Recordati
    Review, Journal:  Novel approach to bone comorbidity in resistant acromegaly. (Pubmed Central) -  Dec 10, 2024   
    Nonetheless, some potential protective effects may derive from vitamin D supplementation and pasireotide therapies, independently from disease status. Aim of this manuscript is to review the current and emerging evidence on skeletal fragility in patients with active and resistant acromegaly.
  • ||||||||||  Review, Journal:  Approach to the patient with controlled acromegaly and acromegalic arthropathy: clinical diagnosis and management. (Pubmed Central) -  Dec 10, 2024   
    However, patients with severe or progressive acromegalic arthropathy require a multidisciplinary approach to determine adequate diagnostics and treatment options. Because of the high prevalence and invalidating character of acromegalic arthropathy, developing evidence-based effective prevention and treatment strategies, preferably by international collaboration within rare disease networks, e.g., Endo-ERN, is a clear unmet need.
  • ||||||||||  Review, Journal:  Skeletal fragility in pituitary disease: how can we predict fracture risk? (Pubmed Central) -  Dec 10, 2024   
    Of note, apart from measures of bone density and bone quality, the estimation of fracture risk in the context of pituitary hyperfunction or hypofunction cannot ignore the evaluation of factors related to the underlying disease, such as its severity and duration, as well as the specific therapies implemented for its treatment. Aim of this review is to provide an up-to-date overview of all major evidence regarding fracture risk prediction in patients with pituitary disease, highlighting the need for a tailored approach that critically integrates all clinical, biochemical, and instrumental data according to the specificities of each disease.
  • ||||||||||  Somavert (pegvisomant) / Pfizer
    Review, Journal:  Impact of medical therapy for hormone-secreting Pituitary tumors on bone. (Pubmed Central) -  Dec 10, 2024   
    Aim of this review is to provide an up-to-date overview of all major evidence regarding fracture risk prediction in patients with pituitary disease, highlighting the need for a tailored approach that critically integrates all clinical, biochemical, and instrumental data according to the specificities of each disease. More research is needed on the effectsof medical therapies for hormone secreting pituitary tumors on bone health.
  • ||||||||||  Review, Journal:  Acromegaly and COVID-19, lessons, and new opportunities. (Pubmed Central) -  Dec 10, 2024   
    Nevertheless, anxiety and depression rates in patients with acromegaly are higher than those in the general population. More studies are needed to assess the true impact of the COVID-19 pandemic on morbidity, mortality, and neuropsychiatric health of patients with acromegaly.
  • ||||||||||  Review, Journal:  REVIEW ARTICLE: CARDIOVASCULAR DISORDERS ASSOCIATED WITH ACROMEGALY: An Update. (Pubmed Central) -  Dec 5, 2024   
    Biochemical control of acromegaly with the recently available multimodal treatment along with better management of cardiovascular co-morbidities has improved the morbidity and mortality rates of patients with acromegaly. However, with the recent advances in the treatment of acromegaly neoplastic causes presently remain as the main leading cause of death in these patients.
  • ||||||||||  Journal:  Prevalence of Neoplasms in Patients with Acromegaly-A Single-Center Polish Study. (Pubmed Central) -  Nov 27, 2024   
    Malignant neoplasms of the thyroid, renal, and stomach type were more common among our subjects compared to the Polish population. This study confirms the association between acromegaly, as well as its activity level and the time from its diagnosis, and the prevalence of neoplasms.
  • ||||||||||  Observational data, Journal:  Echocardiographic and Impedance Cardiography Analysis of Left Ventricular Diastolic Function in Acromegaly Patients. (Pubmed Central) -  Nov 22, 2024   
    RESULTS Poorer parameters of LV diastolic function corresponded to the parameters assessed via ICG: 1) lower ratio E/A was associated with lower SI (P<0.001), CI (P=0.007), VI (P=0.04), ACI (P=0.02), TACI (P=0.005) and higher SVRI (P<0.001), 2) lower E/e' ratio was associated with higher TFC (P=0.03); 3) lower e'avg was associated with lower SI (P=0.01) and CI (P=0.048) and higher SVRI (P=0.03), despite normal LV ejection fraction. CONCLUSIONS Impaired LV diastolic function in AC is associated with impaired pumping function of the heart and higher afterload as assessed on ICG.
  • ||||||||||  Journal:  Shoulder osteoarthritis facilitating the diagnosis of acromegaly. (Pubmed Central) -  Nov 17, 2024   
    The patient's shoulder pain was related to undiagnosed acromegalic arthropathy leading to osteoarthritis and was treated by trans-sphenoidal exeresis of the somatotroph adenoma and a somatostatin analogue. In conclusion, acromegaly should be considered in patients with centred glenohumeral osteoarthritis, as an early diagnosis is essential to limit complications and preserve the quality of life.